Skip to main content
Top
Published in: Annals of Surgical Oncology 1/2016

01-01-2016 | Colorectal Cancer

Linear Relationship of Peritoneal Cancer Index and Survival in Patients with Peritoneal Metastases from Colorectal Cancer

Authors: Matthieu Faron, Raluca Macovei, Diane Goéré, Charles Honoré, Léonor Benhaim, Dominique Elias

Published in: Annals of Surgical Oncology | Issue 1/2016

Login to get access

Abstract

Background

The peritoneal cancer index (PCI) is the main prognostic factor for establishing potentially resectable peritoneal metastases from colorectal cancer. Attempts have been made to set a PCI cutoff on which to base indications of complete cytoreductive surgery (CCRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), but none have reached consensus. The aim of this study was to investigate the relation between the PCI and overall survival (OS).

Methods

We included all consecutive patients homogeneously treated with CCRS and HIPEC between 2003 and 2012. The PCI was calculated at the end of the surgical procedure. The correlation between the PCI and OS was studied using statistical modeling from the simplest to the most complex methods (including linear, quadratic, cubic, and spline cubic). These models were compared by Akaike’s information criteria (AIC).

Results

For the 173 treated patients, 5-year OS reached 41 %. The mean PCI was 10.2 (±6.8). The linear model was the most appropriate to relate the PCI to OS as confirmed with the AIC scoring system. In multivariate analysis, the PCI was confirmed as being the most important prognostic factor (hazard ratio = 1.1 for each supplementary point, p < 0.0001).

Conclusions

There is a perfect linear correlation between the PCI and OS, which precludes setting a unique PCI cutoff for CCRS + HIPEC. Overall, CCRS + HIPEC is generally indicated for PCI < 12 and contraindicated for PCI > 17. Between 12 and 17, other parameters have to be taken into account, such as the presence of extraperitoneal metastases, general performance status, and chemosensitivity.
Literature
1.
go back to reference Chua T, Esquivel J, Pelz J, Morris D. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol. 2013;107:566–73.PubMedCrossRef Chua T, Esquivel J, Pelz J, Morris D. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol. 2013;107:566–73.PubMedCrossRef
2.
go back to reference Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.PubMedCrossRef Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.PubMedCrossRef
3.
go back to reference Quenet F, Goéré D, Metha S, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with and without irinotecan during HIPEC following cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254:294–301.PubMedCrossRef Quenet F, Goéré D, Metha S, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with and without irinotecan during HIPEC following cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254:294–301.PubMedCrossRef
4.
go back to reference Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65–71.PubMedCrossRef Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65–71.PubMedCrossRef
5.
go back to reference Sugarbaker P, Ryan D. Cytoreductive surgery plus HIPEC to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol. 2012;13:362–9.CrossRef Sugarbaker P, Ryan D. Cytoreductive surgery plus HIPEC to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol. 2012;13:362–9.CrossRef
6.
go back to reference Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.PubMedCrossRef Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.PubMedCrossRef
7.
go back to reference da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203:878–86.PubMedCrossRef da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203:878–86.PubMedCrossRef
8.
go back to reference Cashin PH, Graf W, Nygren P, Mahetme H. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort series. Eur J Surg Oncol. 2012;38:509–15.PubMedCrossRef Cashin PH, Graf W, Nygren P, Mahetme H. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort series. Eur J Surg Oncol. 2012;38:509–15.PubMedCrossRef
9.
go back to reference Elias D, Faron M, Stan Iuga B, et al. Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers. Ann Surg. 2015;261:157–63.PubMedCrossRef Elias D, Faron M, Stan Iuga B, et al. Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers. Ann Surg. 2015;261:157–63.PubMedCrossRef
10.
go back to reference Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14:254–61.PubMedCrossRef Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14:254–61.PubMedCrossRef
11.
go back to reference Elias D, Souadka A, Fayard F, Mauguen A, Dumont F, Honoré C, Goéré D. Variation in the peritoneal cancer index scores between surgeons and according to when they are determined (before or after cytoreductive surgery). Eur J Surg Oncol. 2012;38:503–8.PubMedCrossRef Elias D, Souadka A, Fayard F, Mauguen A, Dumont F, Honoré C, Goéré D. Variation in the peritoneal cancer index scores between surgeons and according to when they are determined (before or after cytoreductive surgery). Eur J Surg Oncol. 2012;38:503–8.PubMedCrossRef
12.
go back to reference Gomez Portilla A, Shigeki K, Baratti D, Deraco M. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008;98:228–31.PubMedCrossRef Gomez Portilla A, Shigeki K, Baratti D, Deraco M. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008;98:228–31.PubMedCrossRef
13.
go back to reference Esquivel J, Sticca R, Sugarbaker PH, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol. 2007;14:128–33.PubMedCrossRef Esquivel J, Sticca R, Sugarbaker PH, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol. 2007;14:128–33.PubMedCrossRef
14.
go back to reference Yan TD, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental or standard of care? Ann Surg. 2008;248:829–35.PubMed Yan TD, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental or standard of care? Ann Surg. 2008;248:829–35.PubMed
15.
go back to reference Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and preoperative chemotherapy. Sci World J. 2013;2013:978394.CrossRef Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and preoperative chemotherapy. Sci World J. 2013;2013:978394.CrossRef
16.
go back to reference Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of the complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11:518–21.PubMedCrossRef Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of the complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11:518–21.PubMedCrossRef
18.
go back to reference Elias D, Matsuhisa T, Sideris L, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol. 2004;15:1558–65.PubMedCrossRef Elias D, Matsuhisa T, Sideris L, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol. 2004;15:1558–65.PubMedCrossRef
19.
go back to reference Elias D, Antoun A, Goharin A, et al. Research on the best chemohyperthermia technique for treatment of peritoneal carcinomatosis after complete resection. Int J Surg Invest. 2000;1:431–9. Elias D, Antoun A, Goharin A, et al. Research on the best chemohyperthermia technique for treatment of peritoneal carcinomatosis after complete resection. Int J Surg Invest. 2000;1:431–9.
20.
go back to reference Goere D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257:1065–71.PubMedCrossRef Goere D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257:1065–71.PubMedCrossRef
21.
go back to reference Glehen O, Kwiatowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.PubMedCrossRef Glehen O, Kwiatowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.PubMedCrossRef
22.
go back to reference Goéré D, Souadka A, Faron M Alexis S, et al. Extent of colorectal peritoneal carcinomatosis: attempt at defining a threshold over which HIPEC does not offer survival benefit. A comparative study. Ann Surg Oncol (in press). Goéré D, Souadka A, Faron M Alexis S, et al. Extent of colorectal peritoneal carcinomatosis: attempt at defining a threshold over which HIPEC does not offer survival benefit. A comparative study. Ann Surg Oncol (in press).
Metadata
Title
Linear Relationship of Peritoneal Cancer Index and Survival in Patients with Peritoneal Metastases from Colorectal Cancer
Authors
Matthieu Faron
Raluca Macovei
Diane Goéré
Charles Honoré
Léonor Benhaim
Dominique Elias
Publication date
01-01-2016
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 1/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4627-8

Other articles of this Issue 1/2016

Annals of Surgical Oncology 1/2016 Go to the issue